Einzeltreffer — DigiBib

One of the major problems associated with bare nitinol stent implantation is stent fracture, particularly in the popliteal artery. The purpose of this study was to determine whether drug coated balloons (DCB), interwoven stents (IWS), or plain old balloon angioplasty (POBA) would be suitable for use in distal femoropopliteal (FP) long lesions when an Eluvia stent was implanted proximal to a lesion. This was a multi-center retrospective study enrolling patients undergoing concomitant use of Eluvia with DCB, IWS or POBA for symptomatic atherosclerotic femoropopliteal disease (lesion length > 15 cm) [Rutherford category 2-6] between January 2018 and September 2021. 79 patients with 89 femoropopliteal lesions were enrolled in this study. The mean lesion length and the percentage of the popliteal artery involvement was 24.3 ± 6.4 cm vs 24.0 ± 9.0 cm vs 26.6 ± 6.2 cm and 65.8% vs 89.4% vs 67.8% for the Eluvia + DCB, Eluvia + IWS, and Eluvia + POBA groups, respectively. The 1-year Kaplan-Meier estimates of primary patency and freedom from major adverse limb events (MALEs) were 53.3% vs 44.1% vs 24.2% and 62.4% vs 51.0% vs 28.1%, respectively. Eluvia + POBA was associated with a lower rate for 1-year primary patency (HR 2.49; 95% confidence interval (CI): 1.28-4.87; p = 0.007 and HR 2.38; 95% CI: 1.13-5.77; p = 0.04). In SFA long lesions with proximal Eluvia implantation, distal implantations of either a DCB or IWS were comparable, as opposed to POBA alone which generated worse results.

Titel:	Evaluation of the efficacy of combined device strategies for long femoropopliteal artery disease.
Autor/in / Beteiligte Person:	Iwata, S ; Suzuki, R ; Hosoi, Y ; Tanaka, Y ; Izumi, Y ; Tan, M ; Urasawa, K
Link:	View record at Springer (Volltext)
Zeitschrift:	Cardiovascular intervention and therapeutics, Jg. 39 (2024-07-01), Heft 3, S. 273-283
Veröffentlichung:	Tokyo : Springer, 2024
Medientyp:	academicJournal
ISSN:	1868-4297 (electronic)
DOI:	10.1007/s12928-024-00997-4
Schlagwort:	Humans Male Retrospective Studies Female Aged Stents Alloys Middle Aged Treatment Outcome Prosthesis Design Aged, 80 and over Coated Materials, Biocompatible Popliteal Artery surgery Femoral Artery Peripheral Arterial Disease therapy Peripheral Arterial Disease surgery Angioplasty, Balloon methods Vascular Patency
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Multicenter Study Language: English [Cardiovasc Interv Ther] 2024 Jul; Vol. 39 (3), pp. 273-283. <i>Date of Electronic Publication: </i>2024 Apr 18. MeSH Terms: Popliteal Artery* / surgery ; Femoral Artery* ; Peripheral Arterial Disease* / therapy ; Peripheral Arterial Disease* / surgery ; Angioplasty, Balloon* / methods ; Vascular Patency* ; Humans ; Male ; Retrospective Studies ; Female ; Aged ; Stents ; Alloys ; Middle Aged ; Treatment Outcome ; Prosthesis Design ; Aged, 80 and over ; Coated Materials, Biocompatible References: Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, et al. Treatment effect of drug coated balloons is durable to 3years in the femoropopliteal arteries: long term results of the INPACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11:e005891. (PMID: 10.1161/CIRCINTERVENTIONS.117.005891293261535771683) ; Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541–51. (PMID: 10.1016/S0140-6736(18)32262-130262332) ; Armstrong EJ, Jeon-Slaughter H, Kahlon RS, Niazi KA, Shammas NW, Banerjee S. Comparative outcomes of supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the XLPAD registry. J Endovasc Ther. 2020;27:60–5. (PMID: 10.1177/152660281988565231686573) ; Davaine JM, Quérat J, Guyomarch B, Brennan MA, Costargent A, Chaillou P, et al. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year. Eur J Vasc Endovasc Surg. 2013;46:201–12. (PMID: 10.1016/j.ejvs.2013.05.01023773773) ; Tsujimura T, Takahara M, Iida O, Hiramori S, Hayakawa N, Karashima E, et al. One-year clinical outcomes following implantation of InnovaTM self-expanding nitinol stents in patients with peripheral artery diseases presenting femoropopliteal artery lesions. J Atheroscler Thromb. 2019;26:847–55. (PMID: 10.5551/jat.47399308423506800395) ; Gostev AA, Osipova OO, Cheban AV, Saaya SB, Rubtsun AA, Ignatenko PV, et al. Treatment of long femoropopliteal occlusive lesions with self-expanding interwoven nitinol stent: 24 month outcomes of the STELLA-SUPERA-SIBERIA register trial. J Endovasc Ther. 2023;2:15266028231170124. ; Giannopoulos S, Strobel A, Rudofker E, Kovach C, Kokkosis AA, Armstrong EJ. Outcomes of stented vs nonstented femoropopliteal lesions treated with drug-coated balloon angioplasty. J Endovasc Ther. 2023;30:194–203. (PMID: 10.1177/1526602822107977035179065) ; Kum S, Ipema J, Huizing E, Tan YK, Lim D, Lok IY, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vasc Med. 2021;26:267–72. (PMID: 10.1177/1358863X2098789433733963) ; Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmannet M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS) document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by the European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC), and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816. (PMID: 10.1093/eurheartj/ehx09528886620) ; Rogers JH, Lasala JM. Coronary artery dissection and perforation complicating percutaneous coronary intervention. J Invasive Cardiol. 2004;16:493–9. (PMID: 15353832) ; Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69:3S-125S. (PMID: 10.1016/j.jvs.2019.02.016311599788365864) ; Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–20. (PMID: 10.1002/ccd.2538724402839) ; Bhatt H, Kovach R, Janzer S, George JC. SUPERA stent outcomes in Above-The-Knee IntervEntions: Effects of COMPression and ELongation (SAKE-COMPEL) Sub-study. Cardiovasc Revasc Med. 2018;19:512–5. (PMID: 10.1016/j.carrev.2017.11.00729217340) ; Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–41. (PMID: 10.1016/j.jacc.2014.12.036257440114874808) ; Iida O, Takahara M, Soga Y, Fujihara M, Kawasaki D, Hirano K, et al. A novel angiographic risk score for femoropopliteal interventions. J Endovasc Ther. 2020;27:967–73. (PMID: 10.1177/152660282094847232813589) ; Davaine JM, Querat J, Kaladji A, Guyomarch B, Chaillou P, Costargent A, et al. Treatment of TASC C and D femoropoliteal lesions with paclitaxel eluting stents: 12 month results of the STELLA-PTX registry. Eur J Vasc Endovasc Surg. 2015;50:631–7. (PMID: 10.1016/j.ejvs.2015.07.01826342863) ; Suzuki K, Ueshima D, Higashitani M, Yamauchi Y, Hozawa K, Hayakawa N, et al. Two-year results of endovascular therapy for femoropopliteal arterydisease in Japan during the introduction of drug-eluting devices. Cardiovasc Interv Ther. 2023;38:113–20. (PMID: 10.1007/s12928-022-00873-z35917061) ; Iida O, Takahara M, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, et al. 1-Year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv. 2022;15:630–8. (PMID: 10.1016/j.jcin.2022.01.01935331454) ; Bisdas T, Beropoulis E, Argyriou A, Torsello G, Stavroulakis K. 1-Year All-comers analysis of the eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty. JACC Cardiovasc Interv. 2018;11:957–66. (PMID: 10.1016/j.jcin.2018.03.04629798772) ; Tan M, Takahara M, Soga Y, Mori S, Tsuchiya T, Mazaki T, et al. Three-year clinical outcomes following implantation of LifeStent self-expanding nitinol stents in patients with femoropopliteal artery lesions. Angiology. 2022;73:244–51. (PMID: 10.1177/0003319721104268534493086) ; Scheinert D, Micari A, Brodmann M, Tepe G, Peeters P, Jaff MR, et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv. 2018;11:e005654. (PMID: 10.1161/CIRCINTERVENTIONS.117.00565430354636) ; Soga Y, Takahara M, Iida O, Tomoi Y, Kawasaki D, Tanaka A, et al. Vessel patency and associated factors of drug-coated balloon for femoropopliteal lesion. J Am Heart Assoc. 2023;12:e025677. (PMID: 10.1161/JAHA.122.02567736583431) ; Fujihara M, Takahara M, Iida O, Kawasaki D, Soga Y, Tobita K, et al. Endovascular therapy with interwoven nitinol stent placement after predilation for heavily calcified femoropopliteal artery disease: results of the BURDOCK study. J Vasc Interv Radiol. 2023;S1051–0443(23):00561–4. Contributed Indexing: Keywords: Drug-coated balloon; Eluvia; Femoropopliteal artery; Interwoven nitinol stent; Long lesion; Popliteal artery Substance Nomenclature: 0 (Alloys) ; 2EWL73IJ7F (nitinol) ; 0 (Coated Materials, Biocompatible) Entry Date(s): Date Created: 20240418 Date Completed: 20240610 Latest Revision: 20240610 Update Code: 20240611

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Evaluation of the efficacy of combined device strategies for long femoropopliteal artery disease.